[
    [
        {
            "time": "2018-03-15",
            "original_text": "Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen",
            "features": {
                "keywords": [
                    "CVS",
                    "migraine drugs",
                    "Teva",
                    "Lilly",
                    "Amgen"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds",
            "features": {
                "keywords": [
                    "Merck KGaA",
                    "Vertex",
                    "Gene-Editing",
                    "Compounds"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-02-28",
            "original_text": "Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV",
            "features": {
                "keywords": [
                    "Pharma Stock",
                    "JNJ",
                    "BMY",
                    "Q4 Earnings",
                    "Study Failures",
                    "LLY",
                    "ABBV"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]